Julius-Maximilians-
UNIVERSITÄT
WÜRZBURG

ALUMNI

David Atlan

PhD in Physics.
R&D and Product Supply Management with Procter & Gamble (6 years)
Entrepreneur, co-founder of PhenoSystems SA in 2002, co-founder of Crescential SA in 1999
Expert for the French AERES (bioinformatics)
Guest lecturer at the Faculté de Médecine de Marseille on“Bioinformatique et Analyses Mutationnelles”

Research Areas:

- Software development for genetics, genetic diagnostics, genomics, personalised medicine
- EU project participation up to WP leader: EUROGENTEST (FP6 NoE), Gen2Phen (FP7), NMDchip (FP7), CAPHIV (FP7), Gennet (Eureka)

Which changes affect your scientific area in particular and how do you deal with this challenge in terms of operationalizing changes and predict future developments?
Genome sequencing and associated high-throughput molecular technologies are rapidly gaining importance across the health care spectrum. These techniques provide deep insight into the molecular pathophysiology underlying health and disease in individual patients, and open the door for personalised medicine.
We continuously collaborate with leading academic diagnostics and genomic research groups in Europe, either through bilateral agreements or through EU funded research projects to direct our research efforts.

How accurate do your models and ideas reveal current changes and how much do they help us predicting upcoming future events?
Our software developments evolve constantly to integrate new data sources to help our end-users, molecular diagnostics and genomics researchers to better understand the impact of genetic variations and mutations on the phenotype of their patients, the first step towards personalized medicine, where treatments will be tailored to the genetic profile of the patient.